BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$799M
This Quarter Return
+50.78%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$1.24B
AUM Growth
+$1.24B
(+19%)
Cap. Flow
-$23.1M
Cap. Flow
% of AUM
-1.86%
Top 10 Holdings %
Top 10 Hldgs %
81.83%
Holding
29
New
2
Increased
3
Reduced
11
Closed
3
Top Buys
| 1 |
Dianthus Therapeutics
DNTH
|
$89.8M |
| 2 |
Kyverna Therapeutics
KYTX
|
$78.6M |
| 3 |
Solid Biosciences
SLDB
|
$12M |
| 4 |
Annexon
ANNX
|
$4.6M |
| 5 |
Savara
SVRA
|
$1.66M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$66.1M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$34.1M |
| 3 |
Revolution Medicines
RVMD
|
$31.9M |
| 4 |
Natera
NTRA
|
$25.1M |
| 5 |
Pharvaris
PHVS
|
$13.9M |
Sector Composition
| 1 | Healthcare | 98.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$2.71B
| $248M | 19.91% | 10,473,913 | – | – |
|
|
2
Nuvalent
NUVL
$5.52B
| $203M | 16.28% | 2,697,267 -880,000 | -25% | -$66.1M |
|
|
3
Dianthus Therapeutics
DNTH
$759M
| $89.8M | 7.21% | +2,992,028 | New | +$89.8M |
|
4
Disc Medicine
IRON
$2.07B
| $82M | 6.59% | 1,317,213 -15,332 | -1% | -$955K |
|
|
5
Kyverna Therapeutics
KYTX
$160M
| $78.6M | 6.32% | +3,163,868 | New | +$78.6M |
|
|
6
Pharvaris
PHVS
$1.39B
| $76.3M | 6.14% | 3,303,381 -600,938 | -15% | -$13.9M |
|
|
7
Savara
SVRA
$567M
| $72.5M | 5.83% | 14,565,457 +332,706 | +2% | +$1.66M |
|
|
8
Annexon
ANNX
$226M
| $62.4M | 5.02% | 8,703,268 +641,549 | +8% | +$4.6M |
|
|
9
Solid Biosciences
SLDB
$427M
| $53.7M | 4.32% | 4,034,582 +904,160 | +29% | +$12M |
|
|
10
Madrigal Pharmaceuticals
MDGL
$9.76B
| $52.6M | 4.23% | 196,995 -127,624 | -39% | -$34.1M |
|
11
Mersana Therapeutics
MRSN
$36.5M
| $38.8M | 3.12% | 8,663,673 | – | – |
|
12
Cabaletta Bio
CABA
$133M
| $27.6M | 2.22% | 1,617,364 -382,636 | -19% | -$6.53M |
|
13
X4 Pharmaceuticals
XFOR
$84.2M
| $23.5M | 1.89% | 16,915,784 | – | – |
|
14
Tango Therapeutics
TNGX
$747M
| $23M | 1.85% | 2,892,663 | – | – |
|
15
Arcutis Biotherapeutics
ARQT
$1.86B
| $19.9M | 1.6% | 2,011,687 -988,313 | -33% | -$9.79M |
|
16
Nurix Therapeutics
NRIX
$714M
| $16.6M | 1.34% | 1,132,397 -690,486 | -38% | -$10.2M |
|
|
SYRS
17
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $14.7M | 1.18% | 2,749,808 | – | – |
|
|
MRNS
18
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $12.6M | 1.01% | 1,393,380 -37,678 | -3% | -$341K |
|
19
Atea Pharmaceuticals
AVIR
$267M
| $10M | 0.81% | 2,485,638 | – | – |
|
20
C4 Therapeutics
CCCC
$185M
| $9.33M | 0.75% | 1,142,210 -500,000 | -30% | -$4.09M |
|
21
Rapid Micro Biosystems
RPID
$107M
| $8.18M | 0.66% | 8,434,560 | – | – |
|
22
Invivyd
IVVD
$204M
| $7.99M | 0.64% | 1,799,595 -137,612 | -7% | -$611K |
|
23
Nautilus Biotechnolgy
NAUT
$85.9M
| $5.88M | 0.47% | 2,000,000 | – | – |
|
24
Aclaris Therapeutics
ACRS
$209M
| $3.72M | 0.3% | 3,000,000 -500,000 | -14% | -$620K |
|
25
Xilio Therapeutics
XLO
$36.3M
| $3.03M | 0.24% | 2,805,413 | – | – |
|